AzTrials
AzTrials

Iron Deficiency, Anaemia in ChildrenIDANCT03482076

Iron Deficiency Anemia in Childern With Liver Cirrhosis

A study testing transferrin receptor concentration in people with Iron Deficiency, Anaemia in Children and Liver Cirrhosis, run by Assiut University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Iron deficiency anemia is a common complication of liver cirrhosis in childern and may affects there life this study to improve the outcome of these patients Read more about this study

Who is it for?
Ages 1 month to 18 yearsHealthy volunteers can take part
What is being tested?
transferrin receptor concentration
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
No sites listed yet
Study dates
1 Mar 2019to 1 Jun 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 month to 18 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Who may be able to join

  • all childern with liver cirrhosis in GIT and hepatology unit

Who cannot join

  • Neonates less than one month
  • childern with other liver diseases

Trial locations and contacts

No sites are listed yet.

Nagla Hassan Ibrahim contact

About this study

Official title: Prevelance of Iron Deficiency Anemia in Liver Cirrhosis in Childern

Iron deficiency anemia is a common complication of liver cirrhosis in childern and may affects there life this study to improve the outcome of these patients

Read the detailed description

Patients with cirrhosis are at risk of developing both IDA and anemia of chronic disease concomitantly, and there adverse effects can deteriorate general condition and affect of quality of life in these patients .Also because it is easier to correct IDA than anemia of chronic disease, so this study of the prevalence of IDA helping us in the diagnosis and treatment of IDA and can reduce the need for other diagnostic tests and improve the quality of life in patients with cirrhosis .

Being tested
transferrin receptor concentration
Medical subject headings
Iron Deficiencies, Liver Cirrhosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • transferrin receptor concentrationDiagnostic test

    Sandwich radio-imunoassay

Study groups in NCT03482076
Study groupRoleWhat they receive
transferrin receptor concentrationOtherPrevelance of iron deficiency in this patients
Receives: Diagnostic Test: transferrin receptor concentration

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Prevelance of IDA in liver cirrhosis

    To evaluate results

    Measured: two years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Mar 2018
  2. Study start1 Mar 2019 (estimated)
  3. Primary completion1 Mar 2020 (estimated)
  4. Study completion1 Jun 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03482076
Sponsor's protocol ID
DBK
Acronym
IDA
Status last verified
Mar 2018
First submitted
23 Mar 2018
Last updated
29 Mar 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing transferrin receptor concentration in people with Iron Deficiency, Anaemia in Children and Liver Cirrhosis, run by Assiut University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 29 Mar 2018. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Bahaa Khaled Mohamed (+201002755105 ext. 002, drbahaakhaled@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Prevelance of IDA in liver cirrhosis (time frame: two years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Mar 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in